Ben Shapiro

Trump’s Middle East tour was framed as an economic realignment built on “commerce above chaos,” with Gulf states committing roughly $2 trillion to the U.S. after China had invested about $200 billion in Saudi Arabia and Qatar over 15 years. The announced stack included Saudi Arabia’s $600 billion commitment and $140 billion defense partnership, plus Qatar’s $200 billion package and a $96 billion Boeing order for 160 aircraft, with 50 options. Chamath’s investor case was geographic as well as financial: a 1,000-mile radius around Saudi Arabia reaches 4 billion people, making Gulf infrastructure, AI and logistics a strategic platform rather than a one-off capital haul.

The bullish Gulf thesis came with unresolved counterparty risk around Qatar, Syria and Iran. Ben welcomed deeper Saudi and UAE ties but said Qatar requires “trust but verify,” citing its Hamas relationship, $2 billion of funding, $6.3 billion directed into American universities and restrictions on the U.S. air base it finances. Sanctions relief for Syria and any Iran agreement could work only with enforceable conditions; Iran, he warned, “has never won a war or lost a peace,” so nuclear-enrichment, terrorism-financing and air-defense details matter more than declarations of capitulation.

The trip marked a rejection of Wilsonian interventionism, not a retreat into isolationism. Friedberg and Sacks saw Trump’s speech as respect for different systems of government without the old “our way or the highway” premise; Ben called the emerging split hawkish versus dovish realism, defined by how much verification accompanies commerce. The next strategic question is whether bilateral U.S. deals remain standalone or become an interdependent Saudi-UAE-Israel bloc through an expanded Abraham Accords.

The proposed $400 million Qatari aircraft may be procedurally transferred and retrofitted yet still impose a costly corruption discount on Trump’s agenda. Chamath described a Defense Department–Qatar Ministry of Defense transfer, security retrofit and eventual use by the sitting president; Ben replied that “it looks skeezy,” especially if the aircraft later passes to the Trump presidential library. His practical concern was that adverse optics could overwhelm the week’s commercial wins, reinforce attacks involving Trump-linked crypto ventures and damage the broader agenda if markets weaken.

The China tariff pause removed the crisis premium without yet proving the trade strategy worked. U.S. tariffs fell from 145% to 30%, China’s from 125% to 10%, while the de minimis rule used by Temu and Shein is slated to end. Friedberg nevertheless withheld judgment until agreements deliver regulatory parity, including access for U.S. technology companies and relief from foreign fines. Ben’s chicken-cow-goats analogy captured the risk: removing the most extreme tariffs feels wonderful, but the remaining 10% baseline is still “the chicken,” and policy unpredictability can freeze hiring and capital spending.

The House tax bill was the episode’s clearest bearish macro call: roughly $4.1 trillion of lost revenue and $1.5 trillion of cuts leave annual deficits potentially approaching $2.5 trillion. With federal debt cited around $33 trillion to $37 trillion, the 30-year Treasury “kissing 5%” and refinancing interest potentially nearing $2 trillion annually, Friedberg called the bill “absolute disgrace.” His minimum prescription was no new programs and restoring existing programs to 2019 spending levels; otherwise rising yields, larger interest bills and declining Treasury demand can become a “debt death spiral.”

Drug-price relief and industrial-policy risk are inseparable in Trump’s most-favored-nation order. Friedberg said international reference pricing could reduce pharma profits by roughly 20%-27.5% under stricter implementations while China already matches U.S. clinical-trial enrollment; he also cited the rise in average trial cost from about $250 million in the early 1990s to $2.3 billion in 2025. Ben preferred forcing foreign health systems to pay more rather than “clobbering pharma”; the panel’s nearer-term cost target was the PBM layer, where three dominant intermediaries earn about $3 per processed prescription claim and allegedly generated $7.3 billion in excess specialty-generic profits from 2017 through 2022.

🔗 Original source & video: Trump’s Big Week: Middle East Trip, China Deal, Pharma EO, “Big, Beautiful Bill” with Ben Shapiro